Tag: BIT

Biotron ASX BIT compounds SARS-CoV-2 coronavirus COVID-19

Biotron ruffles through its compound database in search of COVID-19 drug

The chase for effective COVID-19 treatments is well and truly on after biotech company Biotron (ASX: BIT) confirmed it intends to harness its proprietary compounds to develop a treatment for SARS-CoV-...
Biotron ASX BIT HIV immune system evasion BIT225 AIDS

Biotron’s BIT225 drug show to enhance body’s immune response to HIV

Biotron’s (ASX: BIT) lead candidate HIV-1 drug BIT225 has been shown to boost the body’s immune response to HIV by inhibiting viral protein Vpu, while also having an anti-viral effect. The company ...
Biotron ASX BIT Phase 2 trial results HIV drug BIT225 Conference on Retroviral and Opportunistic Infections CROI

Biotron presents further phase 2 trial results for HIV drug BIT225

Clinical stage company Biotron (ASX: BIT) is preparing to present results from its ongoing phase 2 trial into its lead BIT225 drug at the annual Conference on Retroviral and Opportunistic Infections (...
Biotron ASX BIT coronavirus test compounds

Biotron to commence testing of compounds to destroy coronavirus

Australian clinical stage company Biotron (ASX: BIT) has announced it will commence the evaluation of “several promising compounds” which could target various strains of coronavirus, including the dea...
Biotron ASX BIT Phase 2 clinical trial success HIV drug biotech shares

Biotron rides wave of Phase 2 clinical trial success for HIV drug

Biotechnology company Biotron (ASX: BIT) is enjoying its moment in the sun on the back of a skyrocketing share price since news of a successful Phase 2 clinical trial for its BIT225 HIV drug hit the m...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS